Compare FNKO & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNKO | MIST |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.8M | 163.2M |
| IPO Year | 2017 | N/A |
| Metric | FNKO | MIST |
|---|---|---|
| Price | $3.09 | $2.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $7.13 | $6.33 |
| AVG Volume (30 Days) | 894.4K | ★ 3.8M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $928,842,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.22 | $0.63 |
| 52 Week High | $14.65 | $2.77 |
| Indicator | FNKO | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 47.88 | 62.71 |
| Support Level | $2.97 | $2.50 |
| Resistance Level | $3.15 | $2.73 |
| Average True Range (ATR) | 0.15 | 0.16 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 62.16 | 61.76 |
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).